UK DRI announces trial of blood test for Alzheimer’s diagnosis
The UK Dementia Research Institute (DRI) has announced an international research study, which is underway to assess whether a finger-prick…
All articles by Salong Debbarma
Salong Debbarma
-
-
D3 Bio receives FDA clearance to advance KRAS inhibitor trials
D3 Bio has received the US Food and Drug Administration (FDA) clearance for two investigational new drug (IND) applications, enabling…
-
Nxera reports positive outcomes for daridorexant Phase III insomnia study
Nxera Pharma has announced positive top-line results from its Phase III study of daridorexant 50mg, aimed at treating insomnia in…
-
OrsoBio announces clinical trial progress for TLC-2716 metabolic therapy
OrsoBio has announced the publication in Nature Medicine of Phase I clinical trial data for TLC-2716, an oral liver-targeted inverse…
-
Genmab reports top line results in Phase III DLBCL trial
Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting improved progression-free survival…
-
QPS adopts Oracle Argus to advance safety in clinical trials
US-based contract research organisation QPS Holdings (QPS) has implemented a new clinical trial pharmacovigilance system, Oracle Argus, to advance safety…
-
Axsome begins Phase III AXS-14 FORWARD trial for fibromyalgia management
Axsome Therapeutics has initiated the FORWARD Phase III trial evaluating AXS-14 (esreboxetine) for the management of fibromyalgia, with the first…
-
Marea reports positive Phase I results for MAR002 trial in acromegaly
Marea Therapeutics has announced positive top line results from its first-in-human Phase I study of MAR002, an allosteric monoclonal antibody…
-
AbCellera begins Phase II ABCL635 trial for menopause-related VMS
AbCellera has dosed the first patient in the Phase II portion of its ongoing Phase I/II clinical trial evaluating ABCL635…
-
BMS reports positive results in Phase III SCOUT-HCM trial for oHCM
Bristol Myers Squibb (BMS) has announced positive top line results from the Phase III SCOUT-HCM trial assessing Camzyos (mavacamten) for…